Q1 2026 · 13F-HR
Pivotal bioVenture Partners Investment Advisor LLCholdings as filed
Filed 2026-05-14 · accession 0001012975-26-000421
$279.8M
Reported value
13
Positions
2026-03-31
Period end
The Brief · Pivotal bioVenture Partners Investment Advisor LLC · Q1 2026
AI · grounded in 13F
Pivotal bioVenture Partners Investment Advisor LLC established a new position in AVTX valued at $4.4M. The fund also opened a new position in RLYB with a $2.7M investment and increased its stake in TRVI by 23.6%. These additions occurred alongside reductions in holdings for BOLT, which saw a 55% decrease in shares, and OCS, which was trimmed by 26.6%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 92243G108 | PCVX | VAXCYTE INC | $79.8M | 28.5% | 1,372,425 | Common | SHARED |
| H5870P102 | OCS | OCULIS HOLDING AG | $44.7M | 16.0% | 1,680,283 | Common | SHARED |
| 30054Y107 | EVMN | EVOMMUNE INC | $44.3M | 15.8% | 1,926,943 | Common | SHARED |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $31.9M | 11.4% | 1,355,892 | Common | SHARED |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $18.5M | 6.63% | 1,553,726 | Common | SHARED |
| 45257U108 | IMNM | IMMUNOME INC | $16.0M | 5.73% | 732,512 | Common | SHARED |
| 56565P103 | MPLT | MAPLIGHT THERAPEUTICS INC | $12.4M | 4.44% | 611,447 | Common | SHARED |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $11.6M | 4.14% | 591,991 | Common | SHARED |
| 09077V100 | BIOA | BIOAGE LABS INC | $11.4M | 4.08% | 653,374 | Common | SHARED |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $4.4M | 1.58% | 295,933 | Common | SHARED |
| 75120L209 | RLYB | RALLYBIO CORP | $2.7M | 0.96% | 300,579 | Common | SHARED |
| 75629V104 | RXRX | RECURSION PHARMACEUTICALS IN | $1.8M | 0.65% | 595,518 | Common | SHARED |
| 097702203 | BOLT | BOLT BIOTHERAPEUTICS INC | $172,027 | 0.06% | 42,581 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.